Trius Therapeutics, Inc. · San Diego, CA United States (NASDAQ: TSRX)
| 6310 Nancy Ridge Dr., Ste. 101 | Phone: 858-452-0370 |
| San Diego, CA | Fax: 858-677-9975 |
| 92121 | |
| United States | 
Map This Company |
Trius Therapeutics, Inc. Rankings
More Companies in These Related Industries: Pharmaceutical Preparation MfgCompany Description
Trius Therapeutics is an early-stage biopharmaceutical company developing antibiotics to treat life-threatening bacterial infections. Torezolid phosphate, its lead candidate, is an IV- and orally-administered antibiotic being studied for its potential to treat antibiotic-resistant strains of staph infection, known as MRSA (methicillin-resistant Staphylococcus aureus). The company will market torezolid phosphate to hospitals and other health care providers if and when it is approved by the FDA. Trius went public in 2010 through an IPO worth about $50 million. The company intends to use the money to further the development of torezolid phosphate and fund other clinical trials.
Trius Therapeutics, Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: TSRX Single Location |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 53 |
Executives
17 executives listed for Trius Therapeutics, Inc.'s San Diego, CA location.
| Chairman | David Kabakoff | |
|---|---|---|
| President, CEO, and Director | Jeffrey Stein | |
| CFO | John Schmid |